NanoViricides, Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2020. Although the request metadata says “2019 Q4,” this filing is an annual report for FY2020, not a quarterly filing. NanoViricides is a development-stage antiviral drug company; it reported no customers, product sales, or revenue.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.70 million | $5.92 million |
| General and administrative expense | $3.30 million | $2.74 million |
| Total operating expenses / operating loss | $8.00 million | $8.66 million |
| Net loss | $13.45 million | $8.42 million |
| Basic and diluted loss per share | $2.39 | $2.35 |
| Net cash used in operating activities | $6.67 million | $6.80 million |
| Cash and cash equivalents at year-end | $13.71 million | $2.56 million |
| Working capital | $11.83 million | $(0.02) million |
At June 30, 2020, total assets were $23.91 million, including $9.54 million of net property and equipment; current liabilities were $2.16 million and stockholders’ equity was $21.76 million. The company reported a $1.10 million mortgage loan from its CEO/founder, secured by its headquarters, and a $62,843 loan payable. Operating cash use was largely offset by $17.83 million of net financing cash inflows; year-end cash rose $11.15 million. The filing reports no long-term liabilities.
Changes versus the prior year
- Operating expenses fell $663,223: R&D declined $1.23 million, while G&A rose $562,973.
- Net loss increased by $5.02 million, primarily reflecting a $5.85 million noncash loss from changes in derivative fair value, higher G&A, and lower interest income, partly offset by reduced R&D. The derivative loss followed warrant transactions; the company recorded a separate $614,494 gain on warrant settlement.
- Cash increased from $2.56 million to $13.71 million following equity offerings and related-party borrowing. Net proceeds were $7.46 million from the January public offering and approximately $9.22 million from the May offering.
- Common shares outstanding increased to 9.08 million at year-end from 3.84 million a year earlier, reflecting financings and other issuances. A 1-for-20 reverse split took effect in September 2019; presented share data reflect the split.
Business, development status, and outlook
- The company’s primary program shifted toward coronavirus drug development during the pandemic; shingles candidate NV-HHV-101 had been its principal program for much of the fiscal year. NV-HHV-101 had completed IND-enabling safety/toxicology work and was described as IND-ready, but the company deferred filing and trials because COVID-19 could disrupt trial design and execution.
- Coronavirus candidates showed activity in company-reported cell-culture tests against human coronaviruses and in an animal model using hCoV-NL63, a surrogate rather than SARS-CoV-2. These are preclinical findings, not evidence of human safety or efficacy. After year-end, the company nominated NV-CoV-1-R, combining its candidate NV-CoV-1 with remdesivir, for further development; clinical evaluation remained necessary.
- Management planned further coronavirus safety/pharmacology studies, FDA consultation, and an IND filing, with the goal of advancing toward human trials. It gave no reliable development timeline, citing dependence on outside collaborators, staffing constraints, and uncertain work requirements. Shingles IND submission and trials were contingent in part on COVID-19 conditions.
- Management said June 2020 cash could fund planned operations through October 2021 and expected to advance at least one candidate into initial human trials. The filing also estimates substantial additional funding will be needed for later clinical development and commercialization. It gives differing near-term spending estimates in different passages: approximately $11.6 million for the next 12 months in one section and approximately $16 million from October 2020 through October 2021 in another; the filing does not reconcile these estimates clearly.
- After year-end, a July 2020 offering generated approximately $10.53 million net. A separate ATM agreement permits up to $50 million of share sales, but sales are discretionary and would dilute shareholders if made. Management’s cash-runway statements incorporate assumptions and are not guarantees.
- TheraCour, a related party controlled approximately 90% by CEO Anil Diwan, supplies licensed technology and performs development work. The company reported $2.16 million of FY2020 development costs charged by TheraCour and $561,580 payable at year-end. The coronavirus field was covered by a limited MoU while a definitive license was being negotiated. The VZV license includes 15% royalties on net sales and milestone payments; the CEO recused himself from specified related-party discussions.
- The company reported a material weakness in internal control over financial reporting because of inadequate timely review of the 10-K and insufficient personnel/resources; disclosure controls were deemed ineffective at June 30, 2020. It also reported pandemic-related operational disruption and filed its March 2020 quarterly report late.
Key risks and unusual items
- No approved products, revenue, or human clinical-trial experience; continued operating losses and an accumulated deficit of $105.56 million. There is no assurance that candidates will succeed in trials, obtain FDA approval, or reach commercialization.
- Dependence on external CROs and collaborators, limited staffing, and reliance on TheraCour for core technology and development create timing, execution, licensing, and related-party risks.
- Funding beyond early clinical development is uncertain. Further equity issuance could materially dilute shareholders; the ATM provides potential financing capacity, not committed proceeds.
- The $5.85 million derivative fair-value loss materially increased reported net loss and was noncash. The company also exchanged preferred shares for $250,000 of deferred related-party fees, recording a $142,669 loss.
- COVID-19 affected personnel availability, financial-reporting timelines, and planned shingles trial preparation. The company cautions that preclinical results may not predict clinical outcomes.
Important facts for investors to verify
- Current cash, subsequent financing proceeds, actual ATM sales, cash burn, and the basis for management’s stated runway.
- The discrepancy between the filing’s approximately $11.6 million and $16 million near-term spending estimates, and the assumptions underlying later clinical-development funding needs.
- Coronavirus program progress: definitive TheraCour license terms, completion and results of IND-enabling studies, FDA feedback, IND status, and whether human trials began.
- NV-HHV-101 IND filing and trial plans, including the effect of pandemic conditions and collaborator availability.
- Remediation and subsequent testing of the reported internal-control material weakness, and the company’s ability to file accurate reports on time.
- Related-party balances, fees, royalties, milestones, and governance safeguards, including the CEO’s financial interests in TheraCour.